DBVT

DBVT

USD

DBV Technologies S.A. American Depositary Shares

$14.360+0.310 (2.206%)

Preço em tempo real

Healthcare
Biotecnologia
França

Gráfico de preços

Loading Chart...

Métricas-chave

Métricas de mercado
Fundamentos da empresa
Estatísticas de negociação

Métricas de mercado

Abertura

$14.050

Máximo

$15.010

Mínimo

$14.050

Volume

0.07M

Fundamentos da empresa

Capitalização de mercado

521.2M

Setor

Biotecnologia

País

France

Estatísticas de negociação

Volume médio

0.10M

Bolsa de valores

NCM

Moeda

USD

Faixa de 52 semanas

Mínimo $0.441Atual $14.360Máximo $18

Notícias relacionadas

GlobeNewswire

DBV Technologies to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

Châtillon, France, November 4, 2025 DBV Technologies to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference DBV Technologies (TRQX:DBVp), a clinical-stage biopharmaceutical company, today

Ver mais
DBV Technologies to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
GlobeNewswire

DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer

Chatillion, France, November 3, 2025 DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer DBV Technologies (TRQX:DBVp), a clinical-stage biopharmaceutical company, today announced the

Ver mais
DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer
GlobeNewswire

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of October 31, 2025

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of October 31, 2025 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE

Ver mais
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of October 31, 2025
GlobeNewswire

DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors

Châtillon, France, October 30, 2025 DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors DBV Technologies (TRQX:DBVp), (the "Company" or "DBV"), a clinical-stage biopharmaceutical

Ver mais
DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors
GlobeNewswire

DBV Technologies to Participate in Upcoming ACAAI 2025 Annual Scientific Meeting

Châtillon, France, October 30, 2025 DBV Technologies to Participate in Upcoming ACAAI 2025 Annual Scientific Meeting DBV Technologies (TRQX:DBVp), a clinical-stage biopharmaceutical company, today announced upcoming

Ver mais
DBV Technologies to Participate in Upcoming ACAAI 2025 Annual Scientific Meeting
GlobeNewswire

DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq

Châtillon, France, October 29, 2025 DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq DBV Technologies (TRQX:DBVp) (the "Company"), a clinical-stage

Analyst Upgrades

HC Wainwright & Co. Maintains Buy on DBV Technologies, Raises Price Target to $20

HC Wainwright & Co. analyst Andrew S. Fein maintains DBV Technologies with a Buy and raises the price target from $16 to $20.

Mantenha-se atualizado

Defina um alerta de preço, obtenha atualizações de análise de IA e notícias de mercado em tempo real.